975 related articles for article (PubMed ID: 15239086)
1. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.
Wong F; Pantea L; Sniderman K
Hepatology; 2004 Jul; 40(1):55-64. PubMed ID: 15239086
[TBL] [Abstract][Full Text] [Related]
2. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites.
Angeli P; Volpin R; Piovan D; Bortoluzzi A; Craighero R; Bottaro S; Finucci GF; Casiglia E; Sticca A; De Toni R; Pavan L; Gatta A
Hepatology; 1998 Oct; 28(4):937-43. PubMed ID: 9755229
[TBL] [Abstract][Full Text] [Related]
3. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome.
Skagen C; Einstein M; Lucey MR; Said A
J Clin Gastroenterol; 2009 Aug; 43(7):680-5. PubMed ID: 19238094
[TBL] [Abstract][Full Text] [Related]
4. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.
Angeli P; Volpin R; Gerunda G; Craighero R; Roner P; Merenda R; Amodio P; Sticca A; Caregaro L; Maffei-Faccioli A; Gatta A
Hepatology; 1999 Jun; 29(6):1690-7. PubMed ID: 10347109
[TBL] [Abstract][Full Text] [Related]
5. The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites.
Kalambokis G; Economou M; Fotopoulos A; Al Bokharhii J; Pappas C; Katsaraki A; Tsianos EV
Am J Gastroenterol; 2005 Apr; 100(4):879-85. PubMed ID: 15784036
[TBL] [Abstract][Full Text] [Related]
6. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.
Testino G; Ferro C; Sumberaz A; Messa P; Morelli N; Guadagni B; Ardizzone G; Valente U
Hepatogastroenterology; 2003; 50(54):1753-5. PubMed ID: 14696397
[TBL] [Abstract][Full Text] [Related]
7. Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment.
Wong F; Raina N; Richardson R
Gut; 2010 Mar; 59(3):381-6. PubMed ID: 19710033
[TBL] [Abstract][Full Text] [Related]
8. Midodrine and octreotide in treatment of cirrhosis-related hemodynamic complications.
Karwa R; Woodis CB
Ann Pharmacother; 2009 Apr; 43(4):692-9. PubMed ID: 19299324
[TBL] [Abstract][Full Text] [Related]
9. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems.
Guevara M; Ginès P; Bandi JC; Gilabert R; Sort P; Jiménez W; Garcia-Pagan JC; Bosch J; Arroyo V; Rodés J
Hepatology; 1998 Aug; 28(2):416-22. PubMed ID: 9696006
[TBL] [Abstract][Full Text] [Related]
10. Long-term renal sodium handling in patients with cirrhosis treated with transjugular intrahepatic portosystemic shunts for refractory ascites.
Wong W; Liu P; Blendis L; Wong F
Am J Med; 1999 Mar; 106(3):315-22. PubMed ID: 10190381
[TBL] [Abstract][Full Text] [Related]
11. The effect of 1 month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study.
Tandon P; Tsuyuki RT; Mitchell L; Hoskinson M; Ma MM; Wong WW; Mason AL; Gutfreund K; Bain VG
Liver Int; 2009 Feb; 29(2):169-74. PubMed ID: 18492024
[TBL] [Abstract][Full Text] [Related]
12. Transjugular intrahepatic portosystemic shunts for refractory ascites: assessment of clinical and hormonal response and renal function.
Somberg KA; Lake JR; Tomlanovich SJ; LaBerge JM; Feldstein V; Bass NM
Hepatology; 1995 Mar; 21(3):709-16. PubMed ID: 7875668
[TBL] [Abstract][Full Text] [Related]
13. Renal effects of transjugular intrahepatic portosystemic shunt in cirrhosis: comparison of patients with ascites, with refractory ascites, or without ascites.
Gerbes AL; Gülberg V; Waggershauser T; Holl J; Reiser M
Hepatology; 1998 Sep; 28(3):683-8. PubMed ID: 9731559
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular, renal, and neurohumoral responses to single large-volume paracentesis in patients with cirrhosis and diuretic-resistant ascites.
Peltekian KM; Wong F; Liu PP; Logan AG; Sherman M; Blendis LM
Am J Gastroenterol; 1997 Mar; 92(3):394-9. PubMed ID: 9068457
[TBL] [Abstract][Full Text] [Related]
15. Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study.
Appenrodt B; Wolf A; Grünhage F; Trebicka J; Schepke M; Rabe C; Lammert F; Sauerbruch T; Heller J
Liver Int; 2008 Aug; 28(7):1019-25. PubMed ID: 18410283
[TBL] [Abstract][Full Text] [Related]
16. Predictors of clinical response to transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients with refractory ascites.
Deschênes M; Dufresne MP; Bui B; Fenyves D; Spahr L; Roy L; Lafortune M; Pomier-Layrargues G
Am J Gastroenterol; 1999 May; 94(5):1361-5. PubMed ID: 10235219
[TBL] [Abstract][Full Text] [Related]
17. The management of hepatorenal syndrome.
Carl DE; Sanyal A
Minerva Gastroenterol Dietol; 2009 Jun; 55(2):207-26. PubMed ID: 19305378
[TBL] [Abstract][Full Text] [Related]
18. Effects of a 7-day treatment with midodrine in non-azotemic cirrhotic patients with and without ascites.
Kalambokis G; Fotopoulos A; Economou M; Pappas K; Tsianos EV
J Hepatol; 2007 Feb; 46(2):213-21. PubMed ID: 17156883
[TBL] [Abstract][Full Text] [Related]
19. Liver transplant outcomes for patients with hepatorenal syndrome treated with pretransplant vasoconstrictors and albumin.
Rice JP; Skagen C; Said A
Transplantation; 2011 May; 91(10):1141-7. PubMed ID: 21544034
[TBL] [Abstract][Full Text] [Related]
20. Effects of plasma expansion with albumin and paracentesis on haemodynamics and kidney function in critically ill cirrhotic patients with tense ascites and hepatorenal syndrome: a prospective uncontrolled trial.
Umgelter A; Reindl W; Wagner KS; Franzen M; Stock K; Schmid RM; Huber W
Crit Care; 2008; 12(1):R4. PubMed ID: 18197961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
